Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Kazia Therapeutics Limited (KZIA) ADR EACH REP 100 ORD SHS SPON

Sell:$4.32 Buy:$4.48 Change: $0.12 (2.70%)
NASDAQ:0.20%
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$4.32
Buy:$4.48
Change: $0.12 (2.70%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$4.32
Buy:$4.48
Change: $0.12 (2.70%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.

Contact details

Address:
L 5 20 George St
SYDNEY
2077
Australia
Telephone:
+61 (2) 98780088
Website:
www.novogen.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KZIA
ISIN:
US48669G1058
Market cap:
$32.68 million
Shares in issue:
62.17 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Garner
    Chief Executive Officer, Executive Director
  • Gordon Hirsch
    Chief Medical Officer
  • Lilischkis Kimberley
    Clinical & Regulatory Affairs Manager
  • Peng Leong
    Chief Business Officer
  • Stephen Palmer
    Program Director - Degenerative Diseases
  • Justine Stehn
    Director - ATM Program
  • Kate Hill
    Interim Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.